Featured Research

from universities, journals, and other organizations

Drug Breakthrough For Psoriasis Sufferers

Date:
October 14, 2005
Source:
University of Manchester
Summary:
An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.

An international team led by a dermatologist at The University ofManchester has found that treatment with the emerging drug infliximab,marketed as Remicade, can quickly and significantly improve psoriasissymptoms.

Related Articles


The European Infliximab for Psoriasis Efficacy and Safety Study(EXPRESS) was a placebo-controlled trial on 378 patients with moderateto severe psoriasis, to test the efficacy and safety of the drug. Thefindings, published in the 15 October issue of The Lancet, show that80% of patients achieved at least a 75% improvement in symptoms afterten weeks treatment with the drug, as opposed to just 3% of thosereceiving a placebo.

Psoriasis is a chronic condition which results when skin cellsover-produce and accumulate on the surface of the skin, producing red,scaly 'plaques' which may itch and bleed. It is thought to be geneticin origin and is a consequence of an abnormal inflammatory response inthe skin. Around 2% of the population suffer from the disease, withabout 30% of cases considered moderate to severe, but until nowtreatment options have been limited.

Infliximab blocks the activity of 'tumour necrosis factoralpha' (TNF-alpha), a protein involved in inflammation, and the vastmajority of the trial subjects treated with the drug achievedclinically-significant levels of skin clearance. Nearly 60% experiencedat least a 90% improvement in symptoms -- or near-complete skinclearance -- after ten weeks, versus 1% receiving the placebo, whilst26% achieved complete skin clearance (versus 0% receiving the placebo).The improvements continued throughout the 50-week study.

Professor Christopher Griffiths, the University academicleading the trial from the Dermatology Centre at Hope Hospital,Salford, said: "These results indicate that Infliximab is a veryeffective therapy among the newer biological treatments for psoriasis.As a dermatologist, I am very encouraged by the data, which show thatpatients with moderate to severe psoriasis can rapidly achieve skinclearance and that these results can be maintained."

Patients receiving Infliximab also experienced a good responsein nail psoriasis, which is present in 20 -- 50% of psoriasis patientsand often thought of as a treatment-resistant disease. By week 24 ofthe trial, those receiving the drug were experiencing a 56% averagedecrease in this condition, and again this response was maintainedthroughout the trial.

"Physicians' assessments of the patients' conditions backed upour findings," confirmed Professor Griffiths, "with 83% of thosereceiving the drug assessed as having minimal or cleared symptoms byweek 10 of the trial as opposed to just 4% of those receiving theplacebo."



Story Source:

The above story is based on materials provided by University of Manchester. Note: Materials may be edited for content and length.


Cite This Page:

University of Manchester. "Drug Breakthrough For Psoriasis Sufferers." ScienceDaily. ScienceDaily, 14 October 2005. <www.sciencedaily.com/releases/2005/10/051014072910.htm>.
University of Manchester. (2005, October 14). Drug Breakthrough For Psoriasis Sufferers. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2005/10/051014072910.htm
University of Manchester. "Drug Breakthrough For Psoriasis Sufferers." ScienceDaily. www.sciencedaily.com/releases/2005/10/051014072910.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins